BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.

PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula.

SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints.

Inclusion Criteria:

• Volunteers must be over the age of 18.
• Volunteers cannot be smokers.
• Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
• Exercising volunteers must maintain their regimen consistently throughout the course of the 12-week study.
• Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 12-week study.
• Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9

Exclusion Criteria:

• Female volunteers who are pregnant or planning to become pregnant within the next three months.
• Volunteers who are taking any stimulant medications (e.g. Adderall, Adzenys, Dexedrine, Ritalin, Methylphenidate, etc).